GnRH agonist decapeptide
A long-acting synthetic GnRH agonist that ultimately suppresses sex hormone production.
| Class / type | GnRH agonist decapeptide |
|---|---|
| Category | Hormones & Reproductive |
| Status (Jul 2026) | FDA-approved |
Triptorelin initially stimulates LH/FSH release (a transient flare) but with sustained exposure downregulates pituitary GnRH receptors, causing profound suppression of testosterone or estrogen.
FDA-approved for advanced prostate cancer and central precocious puberty; used off-label for endometriosis, uterine fibroids, fertility preservation, and IVF protocols.
Highly effective hormone suppression; long-acting depot formulations dosed every 1-6 months; well-characterized oncology and pediatric use.
Initial testosterone/estrogen 'flare,' hot flashes, bone density loss, sexual dysfunction, mood changes, injection-site reactions; strong suppression makes casual/off-label use risky.
Regarded clinically as reliable and convenient (depot dosing); patients dislike menopausal-type side effects and the initial flare.
FDA-approved as a prescription drug (Trelstar, Triptodur) for prostate cancer and central precocious puberty.